Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of Sunitinib (Sutent) in metastatic castration-resistant prostate cancer after docetaxel
2007-003048-31Phase 2Active
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jul 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sunitinib in prostate cancer (PCa), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Primary efficacy. Started Jul 2007; status: active.
02
Drugs
sunitinib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2007-003048-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003048-31.